CIK 0001649904 · Large accelerated filer
RHYTHM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RYTM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 462159271
- Phone
- 857-264-4280
- Business address
- 222 BERKELEY STREET, 12TH FLOOR, BOSTON, MA, 02116
- Former names
- RHYTHM METABOLIC, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $11,753,355
- in 2 filings, $11.8M under 10b5-1 plans
Net −$11,753,355. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-13 | Garfield Alastair Chief Scientific Officer | Sale 10b5-1 | −800 | $119.17 | $95K | 2,295 |
| 2026-08-13 | Lee Jennifer Kayden EVP, Head of North America | Option exercise 10b5-1 | +35,000 | $24.29 | $850K | 54,233 |
| 2026-08-13 | Lee Jennifer Kayden EVP, Head of North America | Option exercise 10b5-1 | +21,601 | $6.80 | $147K | 75,834 |
| 2026-08-13 | Lee Jennifer Kayden EVP, Head of North America | Sale 10b5-1 | −75,834 | $117.38 | $8.9M | 0 |
| 2026-08-13 | Lee Jennifer Kayden EVP, Head of North America | Option exercise · Stock Options (Right to Buy) 10b5-1 | −35,000 | 36,283 | ||
| 2026-08-13 | Lee Jennifer Kayden EVP, Head of North America | Option exercise · Stock Options (Right to Buy) 10b5-1 | −21,601 | 0 | ||
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Option exercise 10b5-1 | +46,625 | $6.80 | $317K | 112,655 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −2,300 | $111.80 | $257K | 110,355 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −1,000 | $112.86 | $113K | 109,355 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −3,605 | $114.70 | $413K | 105,750 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −14,568 | $115.43 | $1.7M | 91,182 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −18,208 | $116.49 | $2.1M | 72,974 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Sale 10b5-1 | −17,319 | $117.47 | $2.0M | 55,655 |
| 2026-08-12 | Mazabraud Yann EVP, Head of International | Option exercise · Stock Options (Right to Buy) 10b5-1 | −46,625 | 35,875 | ||
| 2026-07-01 | Garfield Alastair Chief Scientific Officer | Option exercise | +4,445 | 12,208 | ||
| 2026-07-01 | Garfield Alastair Chief Scientific Officer | Shares withheld for taxes | −2,150 | $110.41 | $237K | 10,058 |
| 2026-07-01 | Garfield Alastair Chief Scientific Officer | Option exercise · Restricted Stock Units | −4,445 | 8,888 | ||
| 2026-06-24 | JEAN CHRISTOPHE Director | Grant or award · Stock Option (right to buy) | +3,691 | 3,691 | ||
| 2026-06-24 | JEAN CHRISTOPHE Director | Grant or award · Restricted Stock Units | +2,324 | 2,324 | ||
| 2026-06-24 | MCGIRR DAVID W J Director | Grant or award · Stock Option (right to buy) | +3,691 | 3,691 |
Page 2 of 19 · 376 trades